Anthracycline therapy and 24-hour blood-pressure profile in long-term survivors of childhood cancer

Physiological Research

Volumn 59, Issue SUPPL.1, 2010, Pages 97-102

  Novakova Z ^a   Stastna J ^b   Honzikova K ^b   Hrstkova H ^b   Honzikova N ^a   Zavodna E ^a   Fiser B ^a   Honzik P ^c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

Author keywords

Anthracyclines; Blood pressure; Cardiotoxicity; Childhood cancer; Chronobiology

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC;

ADOLESCENT; ADRENERGIC SYSTEM; ADULT; AGE; ARTICLE; BLOOD PRESSURE; CASE CONTROL STUDY; CIRCADIAN RHYTHM; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; SURVIVOR; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD PRESSURE; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; SURVIVORS; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956642197     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. ADAMS MJ, LIPSHULTZ SE: Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 44: 600-606, 2005.
2. BALCÁRKOVÁ P, HRSTKOVÁ H, ELBL L, NOVÁKOVÁ Z, ZÁVODNÁ E, HONZÍKOVÁ N, FIŠER B: Blood pressure and left ventricle function in patients treated with anthracyclines (in Czech). Klinická onkologie 19: 269-273, 2006.
3. BALCÁRKOVÁ P, ELBL L, NOVÁKOVÁ Z, HRSTKOVÁ H, VÍTOVEC J, ŠŤASTNÁ J, KRONTORÁDOVÁ K: Evaluation of left ventricle function in patients treated for malignancy in last years (in Czech). Cor Vasa 50: 378-384, 2008.
4. CARDINALE D, COLOMBO A, SANDRI MT, LAMANTIA G, COLOMBO N, CIVELLI M, MARTINELLI G, VEGLIA F, FIORENTINI C, CIPOLLA CM: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114: 2474-2481, 2006.
5. COLAN SD, PARNESS IA, SPEVAK PJ, SANDERS SP: Developmental modulation of myocardial mechanics: ageand growth-related alterations in afterload and contractility. J Am Coll Cardiol 19: 619-629, 1992.
6. CORNÉLISSEN G, BAKKEN E, DELMORE P, ORTH-GOMÉR K, AKERSTEDT T, CARANDENTE O, CARANDENTE F, HALBERG F: From various kinds of heart rate variability to chronocardiology. Am J Cardiol 66: 863-868, 1990.
7. EKHOLM E, RANTANEN V, BERGMAN M, VESALAINEN R, ANTILA K, SALMINEN E: Docetaxel and autonomic cardiovascular control in anthracycline treated breast cancer patients. Anticancer Res 20: 2045-2048, 2000.
8. ELBL L, HRSTKOVÁ H, TOMÁŠKOVÁ I, BLAŽEK B, MICHÁLEK J: Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in pediatric patients. Eur J Pediatr 164: 678-684, 2005.
9. ELBL L, HRSTKOVÁ H, TOMÁŠKOVÁ I, MICHÁLEK J: Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF) in pediatric patients: echocardiographic follow up. Support Care Cancer 14: 128-136, 2006.
10. GERŠL V, BAJGAR J, KRS O, HRDINA R, PALIČKA V, MAZUROVÁ Y: Changes in cholinesterase activities after daunorubicin administration to rabbits. Hum Exp Toxicol 15: 834-838, 1996.
11. GIANTRIS A, ABDURRAHMAN L, HINKLE A, ASSELIN B, LIPSHULTZ SE: Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 27: 53-68, 1998.
12. HORÁČEK JM, PUDIL R, TICHÝ M, JEBAVÝ L, STARSOVÁ A, PRAUS R, ŽÁK P, MALÝ J: The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukaemia. Neoplasma 52: 430-434, 2005.
13. HRSTKOVÁ H, HONZÍKOVÁ N, FIŠER B, NOVÁKOVÁ Z: Baroreflex sensitivity, blood pressure and heart rate variability in children and adolescents after anthracycline treatment. Scripta Med 74: 187-194, 2001.
14. HRSTKOVÁ H, HONZÍKOVÁ N, NOVÁKOVÁ Z, ZÁVODNÁ E: Some circulatory parameters in children after antitumour therapy. In: Chronobiological Analysis in Pathophysiology of Cardiovascular System. F HALBERG, T KENNER, J SIEGELOVÁ (eds), NCO NZO, Brno, 2003, pp 144-151.
15. JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J, SMIGAL C, THUN MJ: Cancer statistics. CA Cancer J Clin 56: 106-130, 2006.
16. LIPSHULTZ SE, LIPSITZ SR, SALLAN SE, DALTON VM, MONE SM, GELBER RD, COLAN SDE: Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23: 2629-2636, 2005.
17. MERTENS AC, YASUI Y, NEGLIA JP, POTTER JD, NESBIT ME JR, RUCCIONE K, SMITHSON WA, ROBISON LL: Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 19: 3163-3172, 2001.
18. MLADOSIEVIČOVÁ B, FOLTINOVÁ A, PETRÁŠOVÁ H, BERNADIČ M, HULÍN I: Signal averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane. Neoplasma 48: 61-65, 2001.
19. MOTT MG: Anthracycline cardiotoxicity and its prevention: Challenges and opportunities. Pediatr Oncol 824: 221-228, 1997.
20. NOVÁKOVÁ Z, BALCÁRKOVÁ P, HONZÍKOVÁ N, FIŠER B, ZÁVODNÁ E, HRSTKOVÁ H, KRONTORÁDOVÁ K, ŠŤASTNÁ J: Arterial blood pressure and baroreflex sensitivity 1-18 years after completing anthracycline therapy. Neoplasma 54: 162-167, 2007.
21. OEFFINGER KC, MERTENS AC, SKLAR CA, KAWASHIMA T, HUDSON MM, MEADOWS AT, FRIEDMAN DL, MARINA N, HOBBIE W, KADAN-LOTTICK NS, SCHWARTZ CL, LEISENRING W, ROBISON LL: Chronic health condition in adult survivors of childhood cancer. N Engl J Med 355: 1572-1582, 2006.
22. PAI VB, NAHATA MC: Cardiotoxicity of chemotherapeutic agents. Drug Saf 22: 263-302, 2000.
23. SAKAI T, INAGKI R, TANIGUCHI T, SHINOZUKA K, KUNITOMO M, HAYASHI N, ISHII Y, MURAMATSU I: Persistent release of noradrenaline caused by anticancer drug 4́-epidoxorubicin in rat tail artery in vitro. Eur J Pharmacol 356: 25-30, 1998.
24. SCULLY RE, LIPSHULTZ SE: Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol 7: 122-128, 2007.
25. SIMBRE VC, DUFFY SA, DADLANI GH, MILLER TL, LIPSHULTZ SE: Cardiotoxicity of cancer chemotherapy. Implications for children. Pediatr Drugs 7: 187-202, 2005.
26. TANAKA H, THULESIUS O, YAMAGUCHI H, MINO M, KONISHI K: Continuous non-invasive finger blood pressure monitoring in children. Acta Paediatr 83: 646-652, 1994.
27. ZÁVODNÁ E, HRSTKOVÁ H, HONZÍKOVÁ N, NOVÁKOVÁ Z: Autonomous regulation of circulation in children after anthracycline therapy. Scripta Med 75: 195-202, 2002.
28. ZÁVODNÁ E, HRSTKOVÁ H, HONZÍKOVÁ N, NOVÁKOVÁ Z, FIŠER B: Physiological values of finger arterial pressure and baroreflex sensitivity for the age between 11-21 years. Physiol Res 54: 48P, 2005.
29. ZÁVODNÁ E, HRSTKOVÁ H, BALCÁRKOVÁ P, NOVÁKOVÁ Z, HONZÍKOVÁ N, FIŠER B: Blood pressure and baroreflex sensitivity after anthracycline chemotherapy in childhood with respect to fatty acid metabolism. Scripta Med 78: 257-264, 2005.